Therapy News and Research

RSS

BIOTONE announces availability of Cocoa-Comfort Massage Balm

BIOTONE announces Cocoa-Comfort Massage Balm, one of the first balms for the professional massage therapy market. Created from a one-of-a-kind formulation whose leading ingredient Cocoa Butter is nature's ultimate hydrator, the new rich, thick balm gives a slight warming feel when applied at the same time it soothes and balances the skin to enhance its texture and tone.

2 Aug 2010

Octapharma USA receives confirmation of orphan drug exclusivity from FDA for wilate

Octapharma USA has received confirmation of orphan drug exclusivity from the U.S. Food and Drug Administration for wilate (von Willebrand Factor/Factor VIII Concentrate, Human), the replacement therapy developed specifically for von Willebrand Disease. The approval comes from the FDA Office of Orphan Products Development, which helps to advance the development of products that demonstrate promise for the treatment of rare diseases.

2 Aug 2010

ARO uses Elekta VMAT system for prostate cancer patients

In the expansive region of Australasia—which includes Australia, New Zealand and neighboring islands—Auckland Radiation Oncology Centre is the first to use Elekta VMAT, treating a patient with prostate cancer using a single 100-second arc of radiation. Such rapid treatments change the entire therapy experience for these patients, who have had to remain completely still for seven minutes during radiation delivery for each of 37 to 39 separate treatment sessions or "fractions."

From Elekta 2 Aug 2010

Cardioxyl Pharmaceuticals achieves positive results in first clinical study of CXL-1020 for ADHF

Cardioxyl Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing novel therapeutic agents for the treatment of cardiovascular disease, today announced that it has achieved positive safety and tolerability results in the first clinical study of its lead drug candidate, CXL-1020, for the treatment of patients with acute decompensated heart failure. Each year in the United States, more than one million patients are hospitalized with acute heart failure.

2 Aug 2010

U.S. gastroenterologists prescribe Abbott's Humira off-label for treating ulcerative colitis: Report

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that 63 percent of surveyed U.S. gastroenterologists prescribe Abbott's Humira off-label for the treatment of ulcerative colitis. According to the new report entitled Treatment Algorithms in Ulcerative Colitis, surveyed gastroenterologists most often prescribe Humira for ulcerative colitis for patients with loss of response, intolerance or no response to Centocor Ortho Biotech's Remicade.

2 Aug 2010

Repligen receives three additional grants to develop HDAC inhibitors for neurodegenerative diseases

Repligen Corporation today announced that the Company has received three additional grants to support its research program to develop HDAC inhibitors for neurodegenerative diseases. Repligen has received $436,000 in research funding to support the ongoing development of histone deacetylase inhibitors for Friedreich's ataxia.

2 Aug 2010

Study: hGH linked to PROLOR's CTP technology increases half-life, bioactivity

PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today reported publication of a preclinical study in the current on-line edition of the journal Endocrinology showing that human growth hormone (hGH) linked to PROLOR's carboxyl terminal peptide (CTP) technology has significantly increased half-life and bioactivity compared to commercially available hGH. The publication, which is authored by PROLOR researchers, will also be included in the September print edition of Endocrinology.

2 Aug 2010

HDL does not predict heart attack risk after dramatic statin therapy: Study

People with high levels of "good cholesterol," HDL-C, tend to have fewer heart attacks, but HDL-C may offer little protection to people who take statins to lower harmful LDL cholesterol, researchers reported July 21. At Brigham and Women's Hospital in Boston, Dr. Paul Ridker and colleagues analyzed a large study of healthy people who took the statin CRESTOR® (rosuvastatin calcium) to prevent heart attacks. They found that in this group, having high HDL-C was a bad predictor of heart attack risk.

2 Aug 2010

Inpatient rehab helps patient to regain functions lost from injury, illness

After a person receives acute care in a "regular" hospital for catastrophic illness, traumatic injury or a debilitating chronic condition, the next step in the process of recovery often involves a stay at an inpatient rehabilitation, or rehab, facility.Patients often have little warning when they're quickly moved to a rehab facility from acute care. Those who envision a long, leisurely recovery in a hospital or at home may find that the abrupt transition-and new responsibilities in rehab-leaves their heads spinning.

2 Aug 2010

Screening tool kit to measure public facilities

Denis Anson, M.S., O.T.R., director of research and development for the Assistive Technology Research Institute (ATRI) at Misericordia University, has worn a lot of different hats in his professional career.By utilizing the expertise he's acquired during his 30 years of practice and application of assistive technology and occupational therapy strategies, Anson has devised and brought to market the Americans with Disabilities Act — Compliance Assessment Toolkit or ADA-CAT to measure whether public facilities are in compliance with the federal law that was enacted 20 years ago.

2 Aug 2010

Almac's solutions to support biopharma companies by adopting biomarker strategies

Almac today announced the launch of Biomarkers for biopharma a range of solutions specifically designed to meet the needs of the biopharma industry.Almac's solutions are to support biopharma companies in adopting biomarker strategies to enable them to better understand their drug, improve their drug's success rate, improve the drug's value and ultimately maximise their drug's potential.

2 Aug 2010

Scientists identify way to regulate uncontrolled growth of blood vessels

Researchers at the University of California, San Diego School of Medicine have identified a new way to regulate the uncontrolled growth of blood vessels, a major problem in a broad range of diseases and conditions.

2 Aug 2010

Store-and-forward telemedicine as effective as in-person evaluation for planning ear surgery: Study

The 2010 Annual Meeting & OTO EXPO of the American Academy of Otolaryngology - Head and Neck Surgery Foundation,the largest meeting of ear, nose, and throat doctors in the world, will convene September 26-29, in Boston, MA. The official abstract supplement for the annual meeting is now available with the regular August 2010 issue of Otolaryngology - Head and Neck Surgery.

2 Aug 2010

UK Court gives Smith & Nephew right to Appeal in RENASYS patent litigation

The Advanced Wound Management division of Smith & Nephew, Inc., a subsidiary of Smith & Nephew plc. notes the finding of the Patents Court of the High Court of Justice of England and Wales in the patent litigation brought by Kinetic Concepts, Inc.. In that case, the Court found that parts of the Smith & Nephew RENASYS™ EZ and RENASYS GO Negative Pressure Wound Therapy (NPWT) Systems have infringed the patents EP0853950 and EP0777504 in the United Kingdom. Today the Court has given Smith & Nephew the right to Appeal this decision. Our full range of RENASYS products remains on the market."

31 Jul 2010

Cell-of-origin for prostate cancer identified

UCLA scientists have identified for the first time a cell-of-origin for human prostate cancer, a discovery that could result in better predictive and diagnostics tools and the development of new and more effective targeted treatments for the disease.

31 Jul 2010

VBDS secondary to nevirapine use in HIV-positive, pregnant female: Report

Vanishing bile duct syndrome refers to a group of disorders characterized by destruction and disappearance of intrahepatic (inside the liver) bile ducts. Multiple causes have been identified including infections, malignancies, autoimmune conditions and adverse effects of medications. The usual course of this condition is variable and many patients with VBDS respond to treatment of the underlying condition and/ or removal of the offending agent. However, others progress to cirrhosis and end stage liver disease requiring liver transplantation.

31 Jul 2010

Formatech selects Femta's FM101 therapeutic candidate for Fillanthropy program

Today, Formatech, Inc. announced that it has selected Femta's FM101 therapeutic candidate to be enrolled in its Fillanthropy Program. Under this program, Formatech will donate the services required to aseptically fill and finish one lot of the drug candidate for use in support of Femta's upcoming clinical trials.

31 Jul 2010

Kinetic Concepts enters injunction against Smith & Nephew to prohibit infringement of two patents

Kinetic Concepts, Inc. today announced that the High Court of Justice Chancery Division, Patents Court in the United Kingdom has entered an injunction against Smith & Nephew plc prohibiting infringement of two KCI patents relating to negative pressure wound therapy ("NPWT"). The Court stayed the injunction pending appeal, which is expected in October of this year.

31 Jul 2010

Oral contraceptives, HRT may protect women against formation, rupture of brain aneurysms: Study

Results from a new study suggest that oral contraceptives and hormone replacement therapy may yield additional benefit of protecting against the formation and rupture of brain aneurysms in women. The findings from this first-of-its-kind study by a neurointerventional expert from Rush University Medical Center were presented at the Society of Neurointerventional Surgery 7th annual meeting.

31 Jul 2010

Angiotech reports $61.9 million total revenue for second-quarter 2010

Angiotech Pharmaceuticals, Inc. today announced its financial results for the second quarter ended June 30, 2010.

31 Jul 2010

Therapy News and Research

BIOTONE announces availability of Cocoa-Comfort Massage Balm

Octapharma USA receives confirmation of orphan drug exclusivity from FDA for wilate

ARO uses Elekta VMAT system for prostate cancer patients

Cardioxyl Pharmaceuticals achieves positive results in first clinical study of CXL-1020 for ADHF

U.S. gastroenterologists prescribe Abbott's Humira off-label for treating ulcerative colitis: Report

Repligen receives three additional grants to develop HDAC inhibitors for neurodegenerative diseases

Study: hGH linked to PROLOR's CTP technology increases half-life, bioactivity

HDL does not predict heart attack risk after dramatic statin therapy: Study

Inpatient rehab helps patient to regain functions lost from injury, illness

Screening tool kit to measure public facilities

Almac's solutions to support biopharma companies by adopting biomarker strategies

Scientists identify way to regulate uncontrolled growth of blood vessels

Store-and-forward telemedicine as effective as in-person evaluation for planning ear surgery: Study

UK Court gives Smith & Nephew right to Appeal in RENASYS patent litigation

Cell-of-origin for prostate cancer identified

VBDS secondary to nevirapine use in HIV-positive, pregnant female: Report

Formatech selects Femta's FM101 therapeutic candidate for Fillanthropy program

Kinetic Concepts enters injunction against Smith & Nephew to prohibit infringement of two patents

Oral contraceptives, HRT may protect women against formation, rupture of brain aneurysms: Study

Angiotech reports $61.9 million total revenue for second-quarter 2010

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News